Literature DB >> 61054

The use of alpha-adrenergic blockers in benign prostatic obstruction.

M Caine, A Pfau, S Perlberg.   

Abstract

As a result of previous in-vitro studies on the alpha-adrenergic receptor activity of the human prostate and prostatic capsule a trial was made of alpha-adrenergic blockers for the relief of obstructive prostatic symptoms. Considerable benefit was obtained in several groups of patients, as demonstrated either by the relief or prevention of complete retention, or by diminution in residual urine or improvement in urinary flow-rate recordings. A number of illustrative cases are described, and the indications for the use of this treatment are suggested. It is emphasised that this treatment provides symptomatic relief only, and in no sense purports to be a treatment of the enlarged prostate itself.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 61054     DOI: 10.1111/j.1464-410x.1976.tb03013.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  48 in total

Review 1.  Clinical implications of lower urinary tract pharmacology.

Authors:  H N Whitfield
Journal:  Urol Res       Date:  1977

2.  Pathophysiology of lower urinary tract symptoms in the aging male population.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2005

3.  Pathophysiology of benign prostatic hyperplasia in the aging male population.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2005

4.  Correlation between the total volume, transitional zone volume of the prostate, transitional prostate zone index and lower urinary tract symptoms (LUTS).

Authors:  Mario Franciosi; Walter José Koff; Ernani Luis Rhoden
Journal:  Int Urol Nephrol       Date:  2007-01-04       Impact factor: 2.370

Review 5.  Lower urinary tract disease: what are we trying to treat and in whom?

Authors:  Jeremy P W Heaton
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

6.  Catheterisation for nephrectomy?

Authors:  A Pfau
Journal:  Ann R Coll Surg Engl       Date:  1990-07       Impact factor: 1.891

7.  Pharmacologic management of benign prostatic hyperplasia--changing times.

Authors:  A Y Smith
Journal:  West J Med       Date:  1994-11

Review 8.  Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

Review 9.  Early treatment of benign prostatic hyperplasia: implications for reducing the risk of permanent bladder damage.

Authors:  Andrea Tubaro; Simon Carter; Alberto Trucchi; Giorgio Punzo; Stefano Petta; Lucio Miano
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia.

Authors:  K L Lo; M C K Chan; A Wong; S M Hou; C F Ng
Journal:  Int Urol Nephrol       Date:  2009-05-16       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.